2025-2029年全球製藥業生成式人工智慧市場

預計 2024 年至 2029 年間，全球製藥領域生成式人工智慧市場規模將成長 53.808 億美元，預測期內複合年成長率為 26.1%。

本報告對全球製藥業的生成式人工智慧市場進行了全面分析，包括市場規模和預測、趨勢、成長要素和挑戰，以及對約 25 家公司的供應商分析。

本報告對當前市場格局、最新趨勢和促進因素以及整體市場環境進行了最新分析，而整體市場環境的促進因素包括加速藥物發現和開發、增加個人化醫療和治療以及最佳化臨床試驗。

本研究採用客觀的方法，結合一手和二手訊息，包括來自主要行業相關人員的意見。報告包含對主要企業的分析、全面的市場規模數據、區域細分分析以及供應商格局。報告提供歷史數據和預測數據。

研究指出，創新性的醫療和監管文件是未來幾年推動全球製藥業生成式人工智慧市場成長的關鍵因素之一。此外，製藥行銷和商業化的轉型，以及製藥生產和供應鏈管理的改進，預計也將顯著提升市場需求。

目錄

第1章執行摘要

第2章 Technavio 分析

• 價格、生命週期、顧客購買籃、採用率和購買標準分析
• 投入與差異化因素的重要性
• 混淆來源
• 促進因素和挑戰的影響

第3章 市場情勢

• 市場生態系統
• 市場特徵
• 價值鏈分析

第4章 市場規模

• 市場定義
• 市場區隔分析
• 2024年市場規模
• 2024-2029年市場展望

第5章 市場規模表現

• 2019-2023年全球製藥業生成式人工智慧市場
• 方法細分市場分析 2019-2023
• 應用細分市場分析 2019-2023
• 2019-2023年技術細分市場分析
• 2019-2023年區域細分市場分析
• 2019-2023年國家細分市場分析

第6章五力分析

• 五力分析概述
• 買方的議價能力
• 供應商的議價能力
• 新進入者的威脅
• 替代品的威脅
• 競爭威脅
• 市場狀況

第7章 依方法進行市場區隔

• 比較：依方法
• 文字生成
• 影像生成
• 語音生成
• 按方法論分類的市場機會

第8章 按應用進行市場細分

• 比較：透過應用
• 商業的
• 藥物發現
• 臨床開發
• 研究與開發
• 手術
• 按應用分類的市場機會

9. 按技術分類的市場細分

• 比較：按技術
• 深度學習模型
• 自然語言處理
• 生成對抗網路
• 變分自編碼器
• 其他
• 科技市場機遇

第10章 客戶情況

第11章 區域情勢

• 區域細分
• 區域比較
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 法國
  • 英國
  • 義大利
  • 荷蘭
  • 西班牙
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 印尼
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非
  • 以色列
  • 土耳其
• 南美洲
  • 巴西
  • 阿根廷
  • 哥倫比亞
• 各區域的市場機遇

第12章：促進因素、挑戰與機遇

• 市場促進因素
• 市場挑戰
• 促進因素和挑戰的影響
• 市場機遇

第13章 競爭格局

• 概述
• 競爭格局
• 令人困惑的局面
• 產業風險

第14章 競爭分析

• 公司簡介
• 企業排名指數
• 公司市場定位
• AstraZeneca Plc
• Atomwise Inc.
• Bayer AG
• BenevolentAI
• BioXcel Therapeutics Inc.
• Deep Genomics Inc.
• Exscientia plc
• Insilico Medicine
• PathAI Inc.
• Recursion Pharmaceuticals Inc.
• Relay Therapeutics Inc.
• Sanofi SA
• Schrodinger Inc.
• Shenzhen Jingtai Technology Co.Ltd
• Valo Health

第15章附錄

The global generative AI in pharmaceutical industry market is forecasted to grow by USD 5380.8 mn during 2024-2029, accelerating at a CAGR of 26.1% during the forecast period. The report on the global generative AI in pharmaceutical industry market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by accelerating drug discovery and development, enhancing personalized medicine and treatment, optimizing clinical trials.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global generative AI in pharmaceutical industry market is segmented as below:

By Method

• Text generation
• Image generation
• Audio generation

By Application

• Commercial
• Drug discovery
• Clinical development
• Research and development
• Operations

By Technology

• Deep learning models
• Natural language processing
• Generative adversarial networks
• Variational autoencoders
• Others

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • The Netherlands
  • Spain
• APAC
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
• Middle East and Africa
  • UAE
  • South Africa
  • Turkey
• South America
  • Brazil
  • Argentina
  • Colombia
• Rest of World (ROW)

This study identifies the revolutionizing medical and regulatory writing as one of the prime reasons driving the global generative AI in pharmaceutical industry market growth during the next few years. Also, transforming pharmaceutical marketing and commercialization and enhancing pharmaceutical manufacturing and supply chain management will lead to sizable demand in the market.

The report on the global generative AI in pharmaceutical industry market covers the following areas:

• Global generative AI in pharmaceutical industry market sizing
• Global generative AI in pharmaceutical industry market forecast
• Global generative AI in pharmaceutical industry market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global generative AI in pharmaceutical industry market vendors that include AstraZeneca Plc, Atomwise Inc., Bayer AG, BenevolentAI, BioXcel Therapeutics Inc., Deep Genomics Inc., Exscientia plc, Insilico Medicine, PathAI Inc., Recursion Pharmaceuticals Inc., Relay Therapeutics Inc., Sanofi SA, Schrodinger Inc., Shenzhen Jingtai Technology Co.Ltd, Valo Health. Also, the global generative AI in pharmaceutical industry market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Method
  • Executive Summary - Chart on Market Segmentation by Application
  • Executive Summary - Chart on Market Segmentation by Technology
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2024
• 4.4 Market outlook: Forecast for 2024-2029

5 Historic Market Size

• 5.1 Global Generative AI In Pharmaceutical Industry Market 2019 - 2023
  • Historic Market Size - Data Table on Global Generative AI In Pharmaceutical Industry Market 2019 - 2023 ($ million)
• 5.2 Method segment analysis 2019 - 2023
  • Historic Market Size - Method Segment 2019 - 2023 ($ million)
• 5.3 Application segment analysis 2019 - 2023
  • Historic Market Size - Application Segment 2019 - 2023 ($ million)
• 5.4 Technology segment analysis 2019 - 2023
  • Historic Market Size - Technology Segment 2019 - 2023 ($ million)
• 5.5 Geography segment analysis 2019 - 2023
  • Historic Market Size - Geography Segment 2019 - 2023 ($ million)
• 5.6 Country segment analysis 2019 - 2023
  • Historic Market Size - Country Segment 2019 - 2023 ($ million)

6 Five Forces Analysis

• 6.1 Five forces summary
  • Five forces analysis - Comparison between 2024 and 2029
• 6.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2024 and 2029
• 6.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2024 and 2029
• 6.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2024 and 2029
• 6.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2024 and 2029
• 6.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2024 and 2029
• 6.7 Market condition

7 Market Segmentation by Method

• 7.1 Market segments
• 7.2 Comparison by Method
• 7.3 Text generation - Market size and forecast 2024-2029
• 7.4 Image generation - Market size and forecast 2024-2029
• 7.5 Audio generation - Market size and forecast 2024-2029
• 7.6 Market opportunity by Method
  • Market opportunity by Method ($ million)

8 Market Segmentation by Application

• 8.1 Market segments
• 8.2 Comparison by Application
• 8.3 Commercial - Market size and forecast 2024-2029
• 8.4 Drug discovery - Market size and forecast 2024-2029
• 8.5 Clinical development - Market size and forecast 2024-2029
• 8.6 Research and development - Market size and forecast 2024-2029
• 8.7 Operations - Market size and forecast 2024-2029
• 8.8 Market opportunity by Application
  • Market opportunity by Application ($ million)

9 Market Segmentation by Technology

• 9.1 Market segments
• 9.2 Comparison by Technology
• 9.3 Deep learning models - Market size and forecast 2024-2029
• 9.4 Natural language processing - Market size and forecast 2024-2029
• 9.5 Generative adversarial networks - Market size and forecast 2024-2029
• 9.6 Variational autoencoders - Market size and forecast 2024-2029
• 9.7 Others - Market size and forecast 2024-2029
• 9.8 Market opportunity by Technology
  • Market opportunity by Technology ($ million)

10 Customer Landscape

• 10.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

11 Geographic Landscape

• 11.1 Geographic segmentation
• 11.2 Geographic comparison
• 11.3 North America - Market size and forecast 2024-2029
  • 11.3.1 US - Market size and forecast 2024-2029
  • 11.3.2 Canada - Market size and forecast 2024-2029
  • 11.3.3 Mexico - Market size and forecast 2024-2029
• 11.4 Europe - Market size and forecast 2024-2029
  • 11.4.1 Germany - Market size and forecast 2024-2029
  • 11.4.2 France - Market size and forecast 2024-2029
  • 11.4.3 UK - Market size and forecast 2024-2029
  • 11.4.4 Italy - Market size and forecast 2024-2029
  • 11.4.5 The Netherlands - Market size and forecast 2024-2029
  • 11.4.6 Spain - Market size and forecast 2024-2029
• 11.5 APAC - Market size and forecast 2024-2029
  • 11.5.1 China - Market size and forecast 2024-2029
  • 11.5.2 India - Market size and forecast 2024-2029
  • 11.5.3 Japan - Market size and forecast 2024-2029
  • 11.5.4 South Korea - Market size and forecast 2024-2029
  • 11.5.5 Australia - Market size and forecast 2024-2029
  • 11.5.6 Indonesia - Market size and forecast 2024-2029
• 11.6 Middle East and Africa - Market size and forecast 2024-2029
  • 11.6.1 Saudi Arabia - Market size and forecast 2024-2029
  • 11.6.2 UAE - Market size and forecast 2024-2029
  • 11.6.3 South Africa - Market size and forecast 2024-2029
  • 11.6.4 Israel - Market size and forecast 2024-2029
  • 11.6.5 Turkey - Market size and forecast 2024-2029
• 11.7 South America - Market size and forecast 2024-2029
  • 11.7.1 Brazil - Market size and forecast 2024-2029
  • 11.7.2 Argentina - Market size and forecast 2024-2029
  • 11.7.3 Colombia - Market size and forecast 2024-2029
• 11.8 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

12 Drivers, Challenges, and Opportunity

• 12.1 Market drivers
  • Accelerating drug discovery and development
  • Enhancing personalized medicine and treatment
  • Optimizing clinical trials
• 12.2 Market challenges
  • Data privacy and security imperatives in era of accelerated innovation
  • Navigating evolving regulatory and compliance gauntlet
  • Confronting ethical dilemmas and algorithmic bias
• 12.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2024 and 2029
• 12.4 Market opportunities
  • Revolutionizing medical and regulatory writing
  • Transforming pharmaceutical marketing and commercialization
  • Enhancing pharmaceutical manufacturing and supply chain management

13 Competitive Landscape

• 13.1 Overview
• 13.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 13.3 Landscape disruption
  • Overview on factors of disruption
• 13.4 Industry risks
  • Impact of key risks on business

14 Competitive Analysis

• 14.1 Companies profiled
  • Companies covered
• 14.2 Company ranking index
  • Company ranking index
• 14.3 Market positioning of companies
  • Matrix on companies position and classification
• 14.4 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Product / Service
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
  • SWOT
• 14.5 Atomwise Inc.
  • Atomwise Inc. - Overview
  • Atomwise Inc. - Product / Service
  • Atomwise Inc. - Key offerings
  • SWOT
• 14.6 Bayer AG
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key news
  • Bayer AG - Key offerings
  • Bayer AG - Segment focus
  • SWOT
• 14.7 BenevolentAI
  • BenevolentAI - Overview
  • BenevolentAI - Product / Service
  • BenevolentAI - Key offerings
  • SWOT
• 14.8 BioXcel Therapeutics Inc.
  • BioXcel Therapeutics Inc. - Overview
  • BioXcel Therapeutics Inc. - Product / Service
  • BioXcel Therapeutics Inc. - Key offerings
  • SWOT
• 14.9 Deep Genomics Inc.
  • Deep Genomics Inc. - Overview
  • Deep Genomics Inc. - Product / Service
  • Deep Genomics Inc. - Key offerings
  • SWOT
• 14.10 Exscientia plc
  • Exscientia plc - Overview
  • Exscientia plc - Product / Service
  • Exscientia plc - Key offerings
  • SWOT
• 14.11 Insilico Medicine
  • Insilico Medicine - Overview
  • Insilico Medicine - Product / Service
  • Insilico Medicine - Key offerings
  • SWOT
• 14.12 PathAI Inc.
  • PathAI Inc. - Overview
  • PathAI Inc. - Product / Service
  • PathAI Inc. - Key offerings
  • SWOT
• 14.13 Recursion Pharmaceuticals Inc.
  • Recursion Pharmaceuticals Inc. - Overview
  • Recursion Pharmaceuticals Inc. - Product / Service
  • Recursion Pharmaceuticals Inc. - Key offerings
  • SWOT
• 14.14 Relay Therapeutics Inc.
  • Relay Therapeutics Inc. - Overview
  • Relay Therapeutics Inc. - Product / Service
  • Relay Therapeutics Inc. - Key offerings
  • SWOT
• 14.15 Sanofi SA
  • Sanofi SA - Overview
  • Sanofi SA - Business segments
  • Sanofi SA - Key news
  • Sanofi SA - Key offerings
  • Sanofi SA - Segment focus
  • SWOT
• 14.16 Schrodinger Inc.
  • Schrodinger Inc. - Overview
  • Schrodinger Inc. - Business segments
  • Schrodinger Inc. - Key offerings
  • Schrodinger Inc. - Segment focus
  • SWOT
• 14.17 Shenzhen Jingtai Technology Co.Ltd
  • Shenzhen Jingtai Technology Co.Ltd - Overview
  • Shenzhen Jingtai Technology Co.Ltd - Product / Service
  • Shenzhen Jingtai Technology Co.Ltd - Key offerings
  • SWOT
• 14.18 Valo Health
  • Valo Health - Overview
  • Valo Health - Product / Service
  • Valo Health - Key offerings
  • SWOT

15 Appendix

• 15.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 15.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 15.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 15.4 Research methodology
  • Research methodology
• 15.5 Data procurement
  • Information sources
• 15.6 Data validation
  • Data validation
• 15.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 15.8 Data synthesis
  • Data synthesis
• 15.9 360 degree market analysis
  • 360 degree market analysis
• 15.10 List of abbreviations
  • List of abbreviations